AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21439167
Drug: Both SLIT
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both SLIT and supralingual immunotherapy
Trial: 20032907
Drug: modified constraint-induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified constraint-induced movement therapy (mCIT)
Trial: 16478570
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg daily for the first week, then 10 mg for 11 weeks)
Trial: 9159420
Drug: CPA 2
RxNorm normalized name: Cyproterone acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPA 2 mg with 35 microg of ethinylestradiol for 21 days each month (Diane group)
Trial: 9159420
Drug: CPA 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPA 50 mg, days 5‐15, and ethinylestradiol 50 microg, days 5‐25, each month (CPA group)
Trial: 9159420
Drug: Decapeptyl 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decapeptyl 3.75 mg i.m. every 28 days with conjugated oestrogen 0.625 mg, days 1‐21, and medroxyprogesterone acetate 10 mg, days 12‐21 (GnRHa group)
Trial: 8187240
Drug: LDL-apheresis combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-apheresis combined with lipid-lowering drugs
Trial: 31942927
Drug: Inulin-type fructans
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inulin-type fructans (ITFs) treatment
Trial: 21856267
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg, BID), amoxicillin (1000 mg, BID), clarithromycin (500 mg, BID) for 14 days, plus vitamin C (500 mg, BID) and vitamin E (200 IU, BID) for 30 days (Group A)
Trial: 21856267
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg, BID), amoxicillin (1000 mg, BID), clarithromycin (500 mg, BID) for 14 days (Group B)
Trial: 17631400
Drug: Pregabalin 150,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 150, 300, and 600 mg/day
Trial: 16543744
Drug: Intranasal (IN)
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal (IN) diamorphine spray
Trial: 16543744
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) diamorphine
Trial: 8610901
Drug: Acetaminophen 600
RxNorm normalized name: acetaminophen 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 600 mg and codeine 60 mg
Trial: 26634642
Drug: RCT-18 (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCT-18 (180 mg, once weekly for 4 weeks)
Trial: 23868016
Drug: Depression treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depression treatment completion
Trial: 15192622
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy for 30 months
Trial: 9207749
Drug: BCG 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG 0.05 mg + 6 x 10(8) KML
Trial: 9207749
Drug: BCG 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG 0.05 mg + 5 x 10(7) KML
Trial: 9207749
Drug: BCG 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG 0.01 mg + 5 x 10(7) KML
Trial: 3731087
Drug: Cytarabine 2
RxNorm normalized name: cytarabine 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytarabine 2 g/m2/72 h by continuous infusion
Trial: 3731087
Drug: Cytarabine 6
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine 6 g/m2/72 h by continuous infusion
Trial: 26885785
Drug: clin 1.0%-BP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clin 1.0%-BP 3.75% gel
Trial: 26885785
Drug: adap 0.1%-BP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adap 0.1%-BP 2.5% gel
Trial: 9401251
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg daily, 20 mg during diarrhea)
Trial: 8429445
Drug: Modified bovine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified bovine lung surfactant extract (beractant), 4 doses administered.
Trial: 8429445
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (equal volume of air administered).
Trial: 20037567
Drug: milgamma in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: milgamma in combination with diclofenac
Trial: 16810105
Drug: CytoFab (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CytoFab (250 units/kg loading dose, followed by 50 units/kg every 12 hrs for 9 doses)
Trial: 16810105
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 mg/kg human albumin)
Trial: 11061539
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment with 6 IU/m2 body surface/day
Trial: 11061539
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment with 3 IU/m2 body surface/day
Trial: 11061539
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment (both dosages)
Trial: 11061539
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment in GHD children
Trial: 8299405
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g EDTA per infusion over a period of 5‐9 weeks to a total of 57 g EDTA
Trial: 2852945
Drug: Retinol palmitate
RxNorm normalized name: Retinol palmitate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinol palmitate (300,000 I.U. daily)
Trial: 18203048
Drug: Amisulpride 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride 600 mg/day
Trial: 20717044
Drug: Valdecoxib (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib (20 mg intravenous)
Trial: 20717044
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate (GTN patch 10 mg/h)
Trial: 16009103
Drug: Jianpi Qinghua
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jianpi Qinghua Recipe (JPQHR) combined with routine therapy
Trial: 12632840
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg pravastatin per day
Trial: 9785773
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of preventive measures for soccer and running injuries
Trial: 7974685
Drug: Ivermectin, 150‐200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin, 150‐200 micrograms/kg in a single dose
Trial: 7974685
Drug: Albendazole, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole, 400 mg/d for 3 days
Trial: 7974685
Drug: Ivermectin, 150‐200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin, 150‐200 micrograms/kg in a single dose (second treatment course)
Trial: 3141982
Drug: 5 weekly
RxNorm normalized name: donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 weekly fractions of 2 Gy without any prior laparotomy
Trial: 3141982
Drug: 3 weekly
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 weekly fractions of 3.3 Gy after laparotomy
Trial: 26154086
Drug: Acarbose (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (12 mg/kg)
Trial: 26154086
Drug: Trans‐chalcone (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans‐chalcone (12 mg/kg)
Trial: 18430910
Drug: Mitomycin-based treatment
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin-based treatment (n = 341): fluorouracil (1000 mg/m2 on days 1-4 and 29-32) + mitomycin (10 mg/m2 on days 1 and 29) + radiotherapy (45-59 Gy)
Trial: 18430910
Drug: Cisplatin-based treatment
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based treatment (n = 341): fluorouracil (1000 mg/m2 on days 1-4, 29-32, 57-60, and 85-88) + cisplatin (75 mg/m2 on days 1, 29, 57, and 85) + radiotherapy (45-59 Gy; start day = day 57)
Trial: 8865702
Drug: Inhalation anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation anesthesia (GOI)
Trial: 8865702
Drug: Epidural (GOI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural (GOI + continuous epidural infusion 1.5% lidocaine, 5 ml . h‐1)
Trial: 1371291
Drug: Finasteride (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (1, 5, 10, 50, or 100 mg/day for 7 days)
Trial: 1371291
Drug: Finasteride (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (various doses)
Trial: 1371291
Drug: Finasteride (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (2 days treatment)
Trial: 6653057
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg orally at bedtime for four days
Trial: 6653057
Drug: Oxtriphylline 200
RxNorm normalized name: oxtriphylline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxtriphylline 200 mg (equivalent to theophylline 135 mg) orally every eight hours for 10 doses
Trial: 24624390
Drug: Full-mouth ultrasonic
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-mouth ultrasonic debridement followed by monthly supportive periodontal therapy
Trial: 24624390
Drug: Full-mouth ultrasonic
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-mouth ultrasonic debridement followed by supportive periodontal therapy at 3-month intervals
Trial: 19962354
Drug: Oxycodone 10
RxNorm normalized name: oxycodone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 10 mg/day
Trial: 19962354
Drug: Pregabalin (75,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (75, 150, 300, and 600 mg/day)
Trial: 18953194
Drug: Workshop intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Workshop intervention consisting of discussions, didactic information, individual plan formulation, and strategies to cope with moral distress.
Trial: 24223362
Drug: Acetaminophen plus
RxNorm normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen plus honey
Trial: 15165934
Drug: irbesartan 300
RxNorm normalized name: irbesartan 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irbesartan 300 mg/day
Trial: 2433081
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg orally 2 h before and 10 mg at the start of the infusion)
Trial: 2433081
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg 3 h before the infusion)
Trial: 27334415
Drug: Rejection treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rejection treatment including ATG
Trial: 20180787
Drug: OCA (omeprazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCA (omeprazole, clarithromycin, amoxicillin)
Trial: 20180787
Drug: OLA (omeprazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLA (omeprazole, levofloxacin, amoxicillin)
Trial: 20180787
Drug: OACM (omeprazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OACM (omeprazole, amoxicillin for 5 days, followed by omeprazole, clarithromycin, metronidazole for 5 days)
Trial: 20180787
Drug: OALM (omeprazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OALM (omeprazole, levofloxacin, amoxicillin for 5 days, followed by omeprazole, levofloxacin, metronidazole for 5 days)
Trial: 18706008
Drug: i.v./i.a. rt‐PA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v./i.a. rt‐PA therapy
Trial: 18706008
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment arms (i.v./i.a. rt‐PA and i.v. rt‐PA)
Trial: 16798444
Drug: Epidural ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ropivacaine 30 mg diluted to 5 mL (group 5)
Trial: 16798444
Drug: Epidural ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ropivacaine 30 mg diluted to 10 mL (group 10)
Trial: 16798444
Drug: Epidural ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ropivacaine 30 mg diluted to 20 mL (group 20)
Trial: 27001444
Drug: ONO-4232 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO-4232 (various doses)
Trial: 22508200
Drug: HES (130/0.4)
RxNorm normalized name: HE-2200
DrugBank: HE-2200 (DB06257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES (130/0.4) 20 ml/kg + Tranexamic Acid (TA) 10 mg/kg over 30 minutes followed by 1 mg/kg/hr for 12 hours
Trial: 22508200
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's lactate + TA at same dose
Trial: 22508200
Drug: HES (130/0.4)
RxNorm normalized name: HE-2200
DrugBank: HE-2200 (DB06257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES (130/0.4) 20 ml/kg
Trial: 20856830
Drug: Salmeterol-fluticasone 50/500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol-fluticasone 50/500 μg
Trial: 19235434
Drug: Intravesical mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravesical mitomycin C chemotherapy
Trial: 19235434
Drug: Intravesical BCG
RxNorm normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical BCG immunotherapy
Trial: 12842524
Drug: Preoperative steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative steroid treatment (protocol group)
Trial: 10595648
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplement (20 ml per day, equivalent to 0.3 g omega‐6, 3.6 g omega‐3; omega‐6/omega‐3 ratio 0.1)
Trial: 10595648
Drug: Soy lecithin
RxNorm normalized name: Soy Lecithin
DrugBank: Lecithin, soybean (DB14161)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy lecithin supplement (25 g per day, equivalent to 1.5 g omega‐6, 0.5 g omega‐3; omega‐6/omega‐3 ratio 3)
Trial: 10595648
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual diet without any supplement)
Trial: 8932555
Drug: Control (delayed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (delayed treatment)
Trial: 7041935
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg long acting (LA) propranolol
Trial: 7041935
Drug: Carbimazole therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbimazole therapy
Trial: 6377221
Drug: Oral diuretics
RxNorm normalized name: Diabetic Tussin EX Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diuretics (chlorothiazide, 20 mg/kg/dose and spironolactone, 1.5 mg/kg/dose, given twice daily)
Trial: 6377221
Drug: Oral diuretics
RxNorm normalized name: Diabetic Tussin EX Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diuretics
Trial: 31563947
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet top‐dressed with 19 g of the DFM (PROB)
Trial: 22795099
Drug: 35 mg
RxNorm normalized name: papain 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg soy extract daily for 24 weeks
Trial: 22795099
Drug: 70 mg
RxNorm normalized name: silybin 70 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg soy extract daily for 24 weeks
Trial: 22795099
Drug: 35 mg
RxNorm normalized name: papain 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg soy extract after 6 months
Trial: 22795099
Drug: 70 mg
RxNorm normalized name: silybin 70 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg soy extract after 6 months
Trial: 22795099
Drug: 35 mg
RxNorm normalized name: papain 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg soy extract in patients with high bone turnover after 6 months
Trial: 22795099
Drug: 70 mg
RxNorm normalized name: silybin 70 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg soy extract in patients with high bone turnover after 6 months
Trial: 18806043
Drug: IV infusion
RxNorm normalized name: IV INFUSION SET (WINTHROP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of phenylephrine and ephedrine combined in a 100% phenylephrine ratio
Trial: 18806043
Drug: IV infusion
RxNorm normalized name: IV INFUSION SET (WINTHROP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of phenylephrine and ephedrine combined in a 75% phenylephrine ratio
Trial: 18806043
Drug: IV infusion
RxNorm normalized name: IV INFUSION SET (WINTHROP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of phenylephrine and ephedrine combined in a 50% phenylephrine ratio
Trial: 18806043
Drug: IV infusion
RxNorm normalized name: IV INFUSION SET (WINTHROP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of phenylephrine and ephedrine combined in a 25% phenylephrine ratio
Trial: 18806043
Drug: IV infusion
RxNorm normalized name: IV INFUSION SET (WINTHROP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of phenylephrine and ephedrine combined in a 0% phenylephrine ratio (100% ephedrine)
Trial: 15758912
Drug: Allopurinol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (600 mg) administered orally at 15 and 3 hours before ERCP
Trial: 15758912
Drug: Allopurinol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (600 mg)
Trial: 11803347
Drug: Autologous blood
RxNorm normalized name: Banked autologous blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous blood injection (10-20 ml) beneath the staple line
Trial: 10411851
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg BID
Trial: 10411851
Drug: Losartan 25
RxNorm normalized name: LOSARTAN 25MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 25 mg BID
Trial: 10411851
Drug: Hoe‐140 (bradykinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hoe‐140 (bradykinin antagonist) after enalapril
Trial: 10411851
Drug: Hoe‐140 (bradykinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hoe‐140 (bradykinin antagonist) after losartan
Trial: 9395384
Drug: Daily primaquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily primaquine
Trial: 7769294
Drug: Daily doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily doxycycline
Trial: 7769294
Drug: Weekly mefloquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly mefloquine
Trial: 7769294
Drug: Daily vitamin
RxNorm normalized name: Daily Vitamin Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily vitamin alone
Trial: 2178964
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol (0.15 mg.kg‐1 x 2; 30 min apart) (n = 87)
Trial: 2178964
Drug: Intravenous salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous salbutamol (5 micrograms.kg‐1) (n = 89)
Trial: 2178964
Drug: Theophylline (3‐6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (3‐6 mg.kg‐1) infused i.v. 60 min after salbutamol treatment
Trial: 6776300
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered zomepirac sodium at 100 mg
Trial: 6776300
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered zomepirac sodium at 200 mg
Trial: 6776300
Drug: IM administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM administered morphine sulfate at 8 mg
Trial: 28269449
Drug: Implantable gastric
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implantable gastric electric stimulator with automatic daily activity compliance reporting
Trial: 22430968
Drug: PA-824 50
RxNorm normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PA-824 50 mg
Trial: 22430968
Drug: PA-824 100
RxNorm normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PA-824 100 mg
Trial: 22430968
Drug: PA-824 150
RxNorm normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PA-824 150 mg
Trial: 22430968
Drug: PA-824 200
RxNorm normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PA-824 200 mg
Trial: 18848765
Drug: Subcutaneous (SQ)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SQ) Acthar Gel (20 units)
Trial: 18848765
Drug: Subcutaneous (SQ)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SQ) Acthar Gel (80 units)
Trial: 18848765
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) Acthar Gel (20 units)